Tolerx Advancing Novel Type 1 Diabetes Agent Into Phase III Clinical Trial Program Following End Of Phase II FDA Meeting (Medical News Today)
Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases, announced that it is proceeding toward the initiation of a Phase III study of otelixizumab in new-onset type 1 diabetes.

Abraxis BioScience Announces Approval To Market ABRAXANE For Metastatic Breast Cancer In Korea (Medical News Today)
Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, announced that the Korean FDA (KFDA) has granted marketing approval for ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the treatment of breast cancer after failure of standard chemotherapy for metastatic disease.